Table 2 Characteristics of men and women in primary care in Stockholm Region by 2020-02-29 divided into private care and public driven care

Age

 Mean (SD)

67.0 (12.5)

67.0 (12.5)

69.9 (12.6)

69.9 (12.7)

68.4 (12.6)

68.5 (12.7)

 Median [Min, Max]

68.0 [31.0, 100]

68.0 [30.0, 103]

71.0 [31.0, 107]

71.0 [30.0, 109]

70.0 [31.0, 107]

70.0 [30.0, 109]

Diabetes

4859 (28.7%)

11,927 (29.0%)

3483 (19.7%)

8929 (20.7%)

8342 (24.1%)

20,856 (24.8%)

Stroke

639 (3.8%)

1539 (3.7%)

507 (2.9%)

1240 (2.9%)

1146 (3.3%)

2779 (3.30%)

Coronary heart disease CHD

2526 (14.9%)

6146 (15.0%)

1455 (8.2%)

3440 (8.0%)

3981 (11.5%)

9586 (11.4%)

Atrial fibrillation (AF)

2427 (14.4%)

5631 (13.7%)

1771 (10.0%)

4454 (10.3%)

4198 (12.1%)

10,085 (12.0%)

Gout

1155 (6.8%)

2696 (6.6%)

449 (2.5%)

1076 (2.5%)

1604 (4.6%)

3772 (4.50%)

Congestive heart failure

1406 (8.3%)

3278 (8.0%)

1151 (6.5%)

2891 (6.7%)

2557 (7.4%)

6169 (7.3%)

Dementia

35 (0.2%)

117 (0.3%)

20 (0.1%)

123 (0.3%)

55 (0.2%)

240 (0.3%)

Obesity

1500 (8.9%)

3527 (8.6%)

1656 (9.4%)

4097 (9.5%)

3156 (9.1%)

7624 (9.1%)

Antihypertensive therapy

14,767 (96.8%)

36,179 (96.9%)

15,434 (96.3%)

37,840 (96.4%)

30,201 (96.6%)

74,019 (96.6%)

One antihypertensive drug

482 (3.2%)

1165 (3.1%)

593 (3.7%)

1412 (3.6%)

1075 (3.4%)

2577 (3.4%)

Two antihypertensive drugs

5039 (33.0%)

12,668 (33.9%)

6171 (38.5%)

15,140 (38.6%)

11,210 (35.8%)

27,808 (36.3%)

Three or more antihypertensive drugs

9728 (63.8%)

23,511 (63.0%)

9263 (57.8%)

22,700 (57.8%)

18,991 (60.7%)

46,211 (60.3%)

 Thiazides

3295 (21.6%)

8175 (21.9%)

3309 (20.6%)

8509 (21.7%)

6604 (21.1%)

16,684 (21.8%)

 Calcium antagonists

7397 (48.5%)

17,498 (46.9%)

6713 (41.9%)

16,144 (41.1%)

14,110 (45.1%)

33,642 (43.9%)

 Angiotensin receptor blockers

6344 (41.6%)

15,573 (41.7%)

7142 (44.6%)

17,605 (44.9%)

13,486 (43.1%)

33,178 (43.3%)

 ACE inhibitors

6222 (40.8%)

15,301 (41.0%)

4914 (30.7%)

12,027 (30.6%)

11,136 (35.6%)

27,328 (35.7%)

 Beta blockers

6174 (40.5%)

15,066 (40.3%)

6523 (40.7%)

16,098 (41.0%)

12,697 (40.6%)

31,164 (40.7%)

 Aldosterone antagonists

761 (5.0%)

1692 (4.5%)

662 (4.1%)

1565 (4.0%)

1423 (4.6%)

3257 (4.3%)

 Other potassium saving agents

10 (0.1%)

16 (0.0%)

13 (0.1%)

25 (0.1%)

23 (0.1%)

41 (0.1%)

Aspirin in patients with CHD

1807 (71.5%)

4440 (72.2%)

936 (64.3%)

2234 (64.9%)

2743 (68.9%)

6674 (69.6%)

Statin in patients with CHD/AF/diabetes/stroke

4863 (61.4%)

12,148 (63.4%)

3099 (53.1%)

8060 (54.9%)

7962 (57.9%)

20,208 (59.7%)

Statin in patients without CHD/AF/diabetes/stroke

2164 (24.1%)

5783 (26.4%)

2579 (21.7%)

7074 (24.9%)

4743 (22.7%)

12,857 (25.5%)

Anticoagulants or aspirin in patients with stroke

551 (86.2%)

1300 (84.5%)

426 (84.0%)

1038 (83.7%)

977 (85.3%)

2338 (84.1%)

Tobacco counseling

451 (2.8%)

1355 (3.4%)

586 (3.4%)

1577 (3.8%)

1037 (3.1%)

2932 (3.6%)

Alcohol counseling

484 (3.0%)

1236 (3.1%)

196 (1.14%)

509 (1.2%)

680 (2.0%)

1745 (2.1%)

Physical activity counseling

4500 (27.7%)

11,751 (29.7%)

4210 (24.5%)

11,409 (27.3%)

8710 (26.0%)

23,160 (28.4%)

Unhealthy eating counseling

3716 (22.9%)

9516 (24.0%)

3093 (18.0%)

8137 (19.5%)

6809 (20.4%)

17,653 (21.7%)

Counseling lifestyle

4623 (28.4%)

12,156 (30.7%)

4141 (24.1%)

11,247 (26.9%)

8764 (26.2%)

23,403 (28.7%)